In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim: Privacy Has its Virtues

Executive Summary

Boehringer Ingelheim has beaten market growth for the past nine years and may continue to outperform rivals. Part of the secret: its private status affords the group a long-term outlook that's far trickier for its public peers to embrace.
Advertisement

Related Content

In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Boehringer Ingelheim Joins The Corporate Venture Party
Bayer Management Changes May Suggest Deepening Xarelto Concerns
Boehringer-Ingelheim Now RE-LYing On Pradaxa Approval In Stroke Prevention
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel